Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Insider Profile

Butera Salvatore Thomas

Officer | SEC CIK: 0001834339

Comprehensive Trading Performance Summary

The investment footprint of Butera Salvatore Thomas as disclosed via official SEC Form 4 filings provides a critical window into professional capital allocation strategies. By tracking this specific portfolio, investors can analyze how this individual moves capital across different boards and sectors. High-conviction moves by key stakeholders often serve as leading indicators for future market performance, as they reflect the intimate operational knowledge and fiduciary confidence of those closest to the company's decision-making process. Monitoring these strategic accumulation or exit patterns helps bridge the gap between institutional boardrooms and the retail investment community.

Last 7 Days
$0
Buys
$0
Sells
Last 30 Days Trend
$0
Buys
$0
Sells
Filing Date Trade Date Ticker Company Name Industry Relationship Type Price Qty Total, $ Owned After Change, %
2023-12-19 18:59 - VNRX VOLITIONRX LTD In Vitro & In Vivo Diagnostic Substances Officer - CEO - Volition Veterinary BUY $0.83 10,000 $8,300 99,350 +11.2%
2023-12-18 17:38 - VNRX VOLITIONRX LTD In Vitro & In Vivo Diagnostic Substances Officer - CEO - Volition Veterinary BUY $0.77 10,000 $7,700 89,350 +12.6%
2023-11-17 18:01 - VNRX VOLITIONRX LTD In Vitro & In Vivo Diagnostic Substances Officer - CEO - Volition Veterinary BUY $0.81 10,000 $8,100 79,350 +14.4%
2023-08-17 16:40 - VNRX VOLITIONRX LTD In Vitro & In Vivo Diagnostic Substances Officer - CEO - Volition Veterinary BUY $1.21 8,000 $9,680 69,350 +13.0%
2023-06-06 17:14 - VNRX VOLITIONRX LTD In Vitro & In Vivo Diagnostic Substances Officer - CEO - Volition Veterinary BUY $1.59 10,000 $15,900 61,350 +19.5%
2022-12-20 18:30 - VNRX VOLITIONRX LTD In Vitro & In Vivo Diagnostic Substances Officer - CEO - Volition Veterinary BUY $2.27 5,000 $11,350 51,350 +10.8%
2022-12-13 17:59 - VNRX VOLITIONRX LTD In Vitro & In Vivo Diagnostic Substances Officer - CEO - Volition Veterinary BUY $2.09 4,350 $9,092 46,350 +10.4%
2022-11-29 18:57 - VNRX VOLITIONRX LTD In Vitro & In Vivo Diagnostic Substances Officer - CEO - Volition Veterinary BUY $2.21 5,000 $11,050 42,000 +13.5%
2022-08-24 17:52 - VNRX VOLITIONRX LTD In Vitro & In Vivo Diagnostic Substances Officer - CEO - Volition Veterinary BUY $1.60 5,000 $8,000 165,000 +3.1%
2022-08-23 18:14 - VNRX VOLITIONRX LTD In Vitro & In Vivo Diagnostic Substances Officer - CEO - Volition Veterinary BUY $1.64 5,000 $8,200 160,000 +3.2%
2022-06-17 23:05 - VNRX VOLITIONRX LTD In Vitro & In Vivo Diagnostic Substances Officer - CEO - Volition Veterinary BUY $2.05 10,000 $20,500 155,000 +6.9%
2021-11-18 18:39 - VNRX VOLITIONRX LTD In Vitro & In Vivo Diagnostic Substances Officer - CEO-Volition Veterinary BUY $4.02 10,000 $40,200 10,000 +100.0%
SHOW ENTRIES
1-12 OF 12

Tracking Multi-Role Insiders: Butera Salvatore Thomas

High-level stakeholders like Butera Salvatore Thomas, whether acting as directors, officers, or 10% owners, often possess unique cross-sector insights. Monitoring a specific CIK like 0001834339 allows investors to identify recurring patterns of trading success across various industries. When a large 10% shareholder or a key beneficial owner moves capital, it often signals a strategic shift in institutional or private conviction.

SEC Transparency for Key Stakeholders

Every market move made by Butera Salvatore Thomas is a matter of public record under federal law. By aggregating Form 4 filings, we provide transparency into the portfolios of major players who hold significant influence. Following the money of those with a 10% stake or executive power helps bridge the information gap between the boardroom and the retail investor.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.